阿米洛利减少肾小球性蛋白尿中尿激酶/纤溶酶原驱动的肾小管内补体激活
本研究探讨蛋白尿中尿激酶型纤溶酶原激活物(uPA)-纤溶酶原级联是否直接激活肾小管液中的补体C3和C5,并评估阿米洛利的抑制作用。体外实验、podocin敲除小鼠及糖尿病肾病患者数据表明,uPA-纤溶酶原生成过敏毒素C3a和C5a,阿米洛利可减少尿补体激活产物,提示其潜在肾脏保护作用。
要点
- uPA-纤溶酶原级联在肾小管液中直接切割C3和C5,生成C3a和C5a。
- 阿米洛利抑制uPA,减少蛋白尿小鼠尿C3a/C5a及NLRP3炎症小体蛋白。
- 糖尿病肾病患者中阿米洛利显著降低尿C3dg和sC5b-9排泄。
核心结论
- 在蛋白尿条件下,uPA-纤溶酶在肾小管液中生成过敏毒素并促进下游补体激活,该过程对阿米洛利敏感。
研究设计与样本
- 体外/离体研究使用纯化C3、C5、纤溶酶原、尿激酶及健康人尿液。
- 动物实验使用条件性podocin敲除小鼠,分别给予阿米洛利或抗uPA抑制性抗体。
- 临床分析纳入接受高剂量阿米洛利的糖尿病肾病患者尿液和血浆。
主要发现
- uPA与纤溶酶原组合可从完整C3和C5生成C3a和C5a,并被阿米洛利抑制。
- 健康人尿液添加外源性纤溶酶原足以激活补体。
- podocin敲除小鼠出现严重蛋白尿及尿C3a/C5a排泄,阿米洛利治疗4天可逆性减轻,抗uPA抗体使其降低>50%而不改变蛋白尿。
- 抗uPA抗体降低NLRP3炎症小体蛋白,对纤维化标志物无显著影响。
- 糖尿病肾病患者中阿米洛利显著降低尿C3dg和sC5b-9排泄。
临床怎么用
- 阿米洛利可能通过抑制uPA-纤溶酶原介导的肾小管内补体激活,发挥超越利钠和降压的肾脏保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: Proteinuria predicts accelerated decline in kidney function in CKD. The pathologic mechanisms are not well known, but aberrantly filtered proteins with enzymatic activity might be involved. The urokinase-type plasminogen activator (uPA)-plasminogen cascade activates complement and generates C3a and C5a in vitro / ex vivo in urine from healthy persons when exogenous, inactive, plasminogen, and complement factors are added. Amiloride inhibits uPA and attenuates complement activation in vitro and in vivo . In conditional podocin knockout (KO) mice with severe proteinuria, blocking of uPA with monoclonal antibodies significantly reduces the urine excretion of C3a and C5a and lowers tissue NLRP3-inflammasome protein without major changes in early fibrosis markers. This mechanism provides a link to proinflammatory signaling in proteinuria with possible long-term consequences for kidney function. BACKGROUND: Persistent proteinuria is associated with tubular interstitial inflammation and predicts progressive kidney injury. In proteinuria, plasminogen is aberrantly filtered and activated by urokinase-type plasminogen activator (uPA), which promotes kidney fibrosis. We hypothesized that plasmin activates filtered complement factors C3 and C5 directly in tubular fluid, generating anaphylatoxins, and that this is attenuated by amiloride, an off-target uPA inhibitor. METHODS: Purified C3, C5, plasminogen, urokinase, and urine from healthy humans were used for in vitro / ex vivo studies. Complement activation was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, immunoblotting, and ELISA. Urine and plasma from patients with diabetic nephropathy treated with high-dose amiloride and from mice with proteinuria (podocin knockout [KO]) treated with amiloride or inhibitory anti-uPA antibodies were analyzed. RESULTS: The combination of uPA and plasminogen generated anaphylatoxins C3a and C5a from intact C3 and C5 and was inhibited by amiloride. Addition of exogenous plasminogen was sufficient for urine from healthy humans to activate complement. Conditional podocin KO in mice led to severe proteinuria and C3a and C5a urine excretion, which was attenuated reversibly by amiloride treatment for 4 days and reduced by >50% by inhibitory anti-uPA antibodies without altering proteinuria. NOD-, LRR- and pyrin domain-containing protein 3-inflammasome protein was reduced with no concomitant effect on fibrosis. In patients with diabetic nephropathy, amiloride reduced urinary excretion of C3dg and sC5b-9 significantly. CONCLUSIONS: In conditions with proteinuria, uPA-plasmin generates anaphylatoxins in tubular fluid and promotes downstream complement activation sensitive to amiloride. This mechanism links proteinuria to intratubular proinflammatory signaling. In perspective, amiloride could exert reno-protective effects beyond natriuresis and BP reduction. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease, NCT01918488 and Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients, NCT03036748 .
引用
- Isaksson GL, Hinrichs GR, Andersen H, et al. Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria. J Am Soc Nephrol. 2024. PMID: 38254266. doi:10.1681/ASN.0000000000000312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。